| Description |
1 online resource (viii, 227 pages) : illustrations (some color) |
| Contents |
Preface; Contents; Part I: Personalized Therapy in Gastric Cancer; 1: Molecular Pathology of Heredity Gastric Cancer; 1.1 Introduction; 1.2 Hereditary Diffuse Gastric Cancer; 1.3 Gastric Adenocarcinoma and Proximal Polyposis Syndrome; 1.4 Familial Intestinal Gastric Cancer; 1.5 Lynch Syndrome; 1.6 Familial Adenomatous Polyposis/MUTYH- Associated Polyposis/Attenuated Familial Adenomatous Polyposis; 1.7 Peutz-Jeghers Syndrome; 1.8 Juvenile Polyposis Syndrome; 1.9 Li-Fraumeni Syndrome; 1.10 BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer; 1.11 Cowden Syndrome; References |
|
2: Genetics and Molecular Signature of Gastric Cancer2.1 Introduction; 2.2 The Genomic Susceptibility of Gastric Cancer; 2.3 SNPs in Candidate Genes; 2.3.1 Mucins; 2.4 Inflammatory Cytokines and Immune Response Genes; 2.5 Other Genetic Variants; 2.6 Susceptibility Regions Identified by GWAS; 2.6.1 1q22; 2.6.2 5p13.1; 2.6.3 8q24.3; 2.6.4 10q23.33; 2.7 Other Regions; 2.8 Molecular Signature of Gastric Cancer; 2.8.1 Microsatellite Instability and Chromosomal Instability in Gastric Cancer; 2.9 Molecular Subtyping of GC; 2.10 "Driver" Alterations of Gastric Cancer; References |
|
3: Circulating Tumor Cells in Gastric Cancer3.1 Introduction; 3.2 Biology of Circulating Tumor Cells; 3.3 Detection of Circulating Tumor Cells; 3.3.1 Enrichment of Circulating Tumor Cells; 3.3.1.1 Enrichment by Density Gradient Centrifugation; 3.3.1.2 Immune-Magnetic Separation; 3.3.1.3 Size-Based Isolation; 3.3.1.4 CTC-Chip; 3.3.1.5 In Vivo Isolation; 3.3.2 Identification and Characterization of CTCs; 3.4 Ex Vivo and In Vivo Culture of CTCs; 3.4.1 Ex Vivo Culture of CTCs; 3.4.2 In Vivo Culture of CTC; 3.5 Clinical Implications of Circulating Tumor Cells |
|
3.5.1 Prognostic Potentials of CTC in Gastric Cancer3.5.2 Genetic Analysis of CTC; 3.5.2.1 Detection of Tumor-Associated Amplification in CTC; 3.5.2.2 Genomic Tumor Mutation Profile Assessed in CTC; 3.5.2.3 Detection of Tumor-Associated mRNA in CTC; 3.6 Perspectives; References; 4: Customized Chemotherapy in Advanced Gastric Cancer; 4.1 Introduction; 4.2 Chemotherapy in Advanced Gastric Cancer; 4.3 Customized Chemotherapy in Advanced Gastric Cancer; 4.3.1 Platinum; 4.3.2 5-Fluorouracil (5-FU)/Capecitabine/S-1; 4.3.3 Taxanes; 4.3.4 Irinotecan(CPT-11); 4.3.5 Pemetrexed |
|
4.3.6 Other Regimens4.3.7 Markers for Toxicity; References; 5: Targeted Therapy in Advanced Gastric Cancer; 5.1 Novel Comprehensive Classification of Gastric Cancer; 5.2 Targeting the Driver Oncogenes of Tumor Cells; 5.2.1 HER2; 5.2.2 EGFR; 5.2.3 HGF Pathway; 5.2.4 FGFR2; 5.2.5 mTOR; 5.2.6 Cell Cycle; 5.3 Targeting Angiogenesis; 5.3.1 Anti-VEGF Antibody (Bevacizumab); 5.3.2 Anti-VEGFR-2 Antibody (Ramucirumab); 5.3.3 Anti-VEGFR-2 Receptor Tyrosine Kinases (Apatinib); 5.3.4 Angiogenic Receptor Tyrosine Kinases (Sunitinib, Sorafenib, Etc.); 5.4 Immune-Checkpoint Blockade |
| Summary |
This book offers essential information on basic and translational research in gastric cancer, while also illustrating potential opportunities for its application in clinical practice. Gastric cancer is the fourth-most-common cancer globally and the second-leading cause of cancer deaths. It is known to be a heterogeneous disease with varied responses to "one-size-fits-all" treatments. Expanding our knowledge of cancer cell genetics may help us to explore more effective treatments in gastric cancer. The research on molecular mechanisms and its clinical applications, both presented here, will help readers gain an in-depth understanding of gastric cancer and its effective treatment. The book's four sections cover personalized medicine, precise regional therapy, immunotherapy and nanomedicine in gastric cancer. Each part presents the state of art, recent advances and the authors' experiences. Moreover, several interesting cases are described to demonstrate how gastric cancer patients benefit from translational research. This informative and attractively presented book on precision treatment in gastric cancer, including experimental findings and clinical treatment options, offers a valuable resource for oncologists and graduate students working in the field of gastric cancer. Jia Wei, MD, PhD, is an associate professor at Nanjing University and the vice director of Clinical Cancer Institute of Nanjing University. She is now working as an oncologist in the Comprehensive Cancer Center, Affiliated Drum Tower Hospital to Medical School of Nanjing University. Baorui Liu, MD, PhD, is a professor at Nanjing University and director of the Clinical Cancer Institute of Nanjing University. He is also the director of the Comprehensive Cancer Center of Drum Tower Hospital |
| Bibliography |
Includes bibliographical references at the end of each chapters |
| Notes |
Online resource; title from PDF title page (SpringerLink, viewed May 25, 2017) |
| Subject |
Stomach -- Cancer -- Treatment
|
|
Precision Medicine -- methods
|
|
Stomach Neoplasms -- therapy
|
|
Immunotherapy -- methods
|
|
Molecular Targeted Therapy -- methods
|
|
Nanomedicine -- methods
|
|
HEALTH & FITNESS -- Diseases -- General.
|
|
MEDICAL -- Clinical Medicine.
|
|
MEDICAL -- Diseases.
|
|
MEDICAL -- Evidence-Based Medicine.
|
|
MEDICAL -- Internal Medicine.
|
|
Stomach -- Cancer -- Treatment
|
| Form |
Electronic book
|
| Author |
Wei, Jia, editor
|
|
Liu, Baorui, editor
|
| ISBN |
9789811039782 |
|
981103978X |
|
9789811350146 |
|
9811350140 |
|
9789811039799 |
|
9811039798 |
|
